HomeCompareHILS vs GBDC

HILS vs GBDC: Dividend Comparison 2026

HILS yields 843.88% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HILS wins by $4363227.95M in total portfolio value
10 years
HILS
HILS
● Live price
843.88%
Share price
$0.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4363248.80M
Annual income
$3,538,417,394,347.70
Full HILS calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — HILS vs GBDC

📍 HILS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHILSGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HILS + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HILS pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HILS
Annual income on $10K today (after 15% tax)
$71,729.96/yr
After 10yr DRIP, annual income (after tax)
$3,007,654,785,195.55/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, HILS beats the other by $3,007,640,802,071.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HILS + GBDC for your $10,000?

HILS: 50%GBDC: 50%
100% GBDC50/50100% HILS
Portfolio after 10yr
$2181634.83M
Annual income
$1,769,216,922,540.77/yr
Blended yield
81.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

HILS
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.3
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HILS buys
0
GBDC buys
0
No recent congressional trades found for HILS or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHILSGBDC
Forward yield843.88%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$4363248.80M$20.85M
Annual income after 10y$3,538,417,394,347.70$16,450,733.83
Total dividends collected$4298592.53M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: HILS vs GBDC ($10,000, DRIP)

YearHILS PortfolioHILS Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$95,088$84,388.19$12,492$1,791.70+$82.6KHILS
2$851,681$749,936.40$16,527$3,160.58+$835.2KHILS
3$7,188,859$6,277,560.82$23,588$5,904.90+$7.17MHILS
4$57,213,181$49,521,101.51$37,141$11,901.65+$57.18MHILS
5$429,552,802$368,334,698.45$66,205$26,463.38+$429.49MHILS
6$3,044,138,048$2,584,516,550.07$137,452$66,612.65+$3044.00MHILS
7$20,374,845,574$17,117,617,861.98$342,372$195,298.53+$20374.50MHILS
8$128,876,441,910$107,075,357,146.57$1,053,292$686,954.33+$128875.39MHILS
9$770,870,472,639$632,972,679,795.13$4,111,439$2,984,416.95+$770866.36MHILS
10$4,363,248,800,072$3,538,417,394,347.70$20,849,974$16,450,733.83+$4363227.95MHILS

HILS vs GBDC: Complete Analysis 2026

HILSStock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Full HILS Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HILS vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HILS vs SCHDHILS vs JEPIHILS vs OHILS vs KOHILS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.